Research: GlaxoSmithKline Pharmaceuticals

Articles found below have been submitted through various PR and news sources and don’t necessary reflect the views of SalesTrax or its employees.

Pharmaceutical Business Review

2009-08-11 12:03
Ranbaxy Receives FDA Approval For All Strengths Of Sumatriptan
Tablets have the same therapeutic effect as that of the reference listed drug - Imitrex by GlaxoSmithKline

2009-07-06 04:04
GlaxoSmithKline Discontinues Development Of Remogliflozin
Discontinuation as a result of evaluating circumstances, including the development status of SGLT2 inhibitors by competitors

2009-06-24 04:03
GSK, Chroma Therapeutics Form Alliance
GlaxoSmithKline to invest in Chroma? Series D equity financing

2009-06-04 04:03
Concert Pharmaceuticals, GlaxoSmithKline Collaborate For Deuterium-containing Medicines
Concert to receive $35 million in upfront payments, and will provide GSK with deuterium-modified versions of three GSK pipeline compounds for development.

2009-06-02 12:03
FDA Approves GlaxoSmithKline' Lamictal XR For Epilepsy Treatment
GlaxoSmithKline has announced that the US Food and Drug Administration (FDA) has approved Lamictal XR (lamotrigine) Extended-Release tablets as once-a-day add-on therapy for epilepsy patients with partial onset seizures.

2009-06-01 04:03
GlaxoSmithKline, Genmab Wins FDA Recommendation For Arzerra
GlaxoSmithKline and Genmab have announced that FDA's Oncologic Drugs Advisory Committee (ODAC) has voted ten to three that the Arzerra (ofatumumab) data are reasonably likely to predict clinical benefit for patients with chronic lymphocytic leukemia (CLL), whose disease is refractory to fludarabine and alemtuzumab.

2010-12-30 20:00
Shrink It, Cure It
GlaxoSmithKline Chief Andrew Witty has a plan to save the struggling drugmaker: Turn it into a collection of entrepreneurial biotech outfits.

2010-05-10 12:00
GlaxoSmithKline On FDA's Rotavirus Vaccine Concerns
A statement in response to the FDA's Advisory Committee Meeting on rotavirus vaccines.

2010-01-20 16:00
GlaxoSmithkline's Malaria Plan: Limit Profits, Open Labs
Chief Andrew Witty lays out his ideas for tackling diseases that plague the Third World.